| Jenna Sue Fountain, | |
|
221 E King St, Andover, KS 67002-8964 | |
| (316) 733-5047 | |
| Not Available |
| Full Name | Jenna Sue Fountain |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 221 E King St, Andover, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093582942 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 03267-T (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jenna Sue Fountain, 520 E Augusta Ave, Augusta, KS 67010-2100 Ph: () - | Jenna Sue Fountain, 221 E King St, Andover, KS 67002-8964 Ph: (316) 733-5047 |
News Archive
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains.
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
Facing challenges in their home state, top executives of Boston-based Partners HealthCare System told a national audience of investors Monday that they will create a bold "new medical model" by integrating hospitals and their medical services with insurance products and by drawing patients from across the country. Speaking at the J.P. Morgan Healthcare Conference, Partners' chief executive, Gary L. Gottlieb, said his organization, which owns Harvard-affiliated Massachusetts General and Brigham and Women's hospitals in Boston, plans to improve medical care and lower costs by further expanding its network of community hospitals and primary care physicians in Eastern Massachusetts (Weisman, 1/14).
Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.
› Verified 9 days ago
Danielle Leigh Forbes, TLMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 221 E King St, Andover, KS 67002 Phone: 316-733-5047 | |
Jill Roberts, LMLP Psychologist Medicare: Medicare Enrolled Practice Location: 217 W Ira Ct, Andover, KS 67002 Phone: 316-733-5047 | |
Mr. John H Koppenhaver Iv, MA, LCP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 217 W Ira Ct, Andover, KS 67002 Phone: 316-733-5047 Fax: 316-733-5060 | |
Darci Elizabeth Klein, MS Psychologist Medicare: Medicare Enrolled Practice Location: 217 W Ira Ct, Andover, KS 67002 Phone: 316-733-5047 | |
Jared Samuel Ohm, TLMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 217 W Ira Ct, Andover, KS 67002 Phone: 316-733-5047 | |
Katherine Rayne Leahy, PSYD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 217 W Ira Ct, Andover, KS 67002 Phone: 316-733-5047 |